Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Roche/Genentech head deal-maker moves on after 14 years
View:
Post by Noteable on May 28, 2024 11:45am

Roche/Genentech head deal-maker moves on after 14 years

May 28, 2024 - James Sabry, global head at Roche Pharma Partnering, is moving on from the Swiss pharma giant. 

He will be succeeded by Boris Zatra, Roche’s head of group business development, who will take on the title of head of corporate business development on July 1. He will report to Roche CEO Thomas Schinecker. 

Zatra, presently Head of Group Business Development, will be appointed as the Head of Corporate Business Development. This new role will merge the functions of Pharma Partnering and Group Business Development, as stated in Roche’s Monday announcement. Zatra has been with Roche since 2012, starting his journey in Basel.


https://www.mmm-online.com/home/channel/people-moves/james-sabry-roche-global-head-of-partnering-retires/
Comment by 13X2413 on May 28, 2024 1:08pm
Hence the enormous interest in Onc. (Eye roll) I'm feeling better about the pick up in volume and stock price. (2nd eye roll)
Comment by Peladawn on May 28, 2024 5:32pm
If you think there's no hope, then why don't you go away?......(middle finger outstretched)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities